News
22 Sep 2020
Daewoong to export gastric acid blocker to Mexico
Daewoong Pharmaceutical has signed a deal worth $50 million to supply Mexico’s Moksha8 with gastric acid blocker Fexuprazan. Given the local authorities' approval plan, Moksha8 aims to launch Fexuprazan in the second half of 2022.
Mentioned Companies
Daewoong Pharmaceutical Co.,Ltd
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance